Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in ...

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast ...

Olympic great described this year's star-studded cancer-research concert as his most “epic" yet. The benefit promises to ...

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...

The Constitution State leads in its five-year survival rate and high-risk screening rate, the American Lung Association said.

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in ...

Zuby Ejiofor is the headline to fifth-ranked St. John’s robust frontcourt, the Big East preseason player of the year. Dillon Mitchell and Bryce Hopkins are the flashy additions, talented and ...

Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...

WASHINGTON (AP) — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors. People with advanced lung or skin ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors. People with advanced lung or skin cancer who were ...